News25/Ratings7
News · 26 weeks45+200%
2026-04-192026-10-11
Mix1290d
- Insider4(33%)
- Other3(25%)
- SEC Filings3(25%)
- Earnings1(8%)
- Analyst1(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by TriSalus Life Sciences Inc.4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSEC Form 4 filed by TriSalus Life Sciences Inc.4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSEC Form 4 filed by TriSalus Life Sciences Inc.4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSEC Form 4 filed by TriSalus Life Sciences Inc.4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- SECTriSalus Life Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- PRTriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver EmbolizationTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery™ (PEDD) portfolio. TriNav® Advance expands TriSalus' portfolio of PEDD devices, adding access to small, distal vessels, via a compatible delivery microcatheter, while preserving PEDD's enhanced therapeutic delivery and off-target protection. Interventional radiologists can now pair
- ANALYSTH.C. Wainwright initiated coverage on TriSalus Life Sciences with a new price targetH.C. Wainwright initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00
- PRTriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment ConferenceTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference. Management will participate in one-on-one meetings on Monday, September 14 and Tuesday, September 15, and will participate in a Fireside chat on Monday, September 14 at 5:00 p.m. ET. A webcast replay of the Fireside chat will be available for 90 days following the Fire
- SECSEC Form 10-Q filed by TriSalus Life Sciences Inc.10-Q - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- PRTriSalus Life Sciences Reports Second Quarter 2026 ResultsGenerated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting Conference Call and Webcast today at 4:30pm ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. "We delivered a second quarter marked by year-over-year and strong sequentia
- SECTriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- PRTriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth ConferenceTriSalus Life Sciences® Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings on Tuesday, August 11 and Wednesday, August 12, and participate in a fireside chat on Wednesday, August 12 at 8:30 a.m. ET. A webcast replay of the corporate overview will be available for 90 days following the presentation in the Events
- PRTriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference CallTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the call, dial-in details will be provided in an auto-generated email containing a link
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.SCHEDULE 13G/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)
- INSIDERChief Financial Officer Patience David covered exercise/tax liability with 14,650 shares, decreasing direct ownership by 5% to 261,107 units (SEC Form 4) (tax liability)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERCEO and President Szela Mary T was granted 3,990 shares, increasing direct ownership by 0.37% to 1,077,683 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERSzela Mary T increased direct ownership by 101% to 1,023,826 units (SEC Form 5)5 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERChief Commercial Officer Marshak Richard was granted 561 shares, increasing direct ownership by 0.44% to 128,319 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERMarshak Richard increased direct ownership by 383% to 131,758 units (SEC Form 5)5 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERChief Medical Officer Marshall Richard Henry was granted 60,000 shares, increasing direct ownership by 200% to 90,000 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERNew insider Marshall Richard Henry claimed ownership of 30,000 shares (SEC Form 3)3 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- PRTriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver CancerNewly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share clinical experience and patient case examples TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly published real-world outcomes study demonstrating th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.SCHEDULE 13G/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)
- INSIDERChief Commercial Officer Marshak Richard sold $1,450 worth of shares (543 units at $2.67), decreasing direct ownership by 0.43% to 125,101 units (SEC Form 4) to cover withholding tax4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
TLSI FAQ
6 questionsWhere does TLSI stock trade?
TriSalus Life Sciences Inc. (TLSI) is listed on NASDAQ.What sector and industry is TLSI in?
TriSalus Life Sciences Inc. operates in the Health Care sector, Medical Specialities industry.When did TriSalus Life Sciences Inc. go public?
TriSalus Life Sciences Inc. (TLSI) completed its IPO in 2021.What are analysts saying about TLSI?
TriSalus Life Sciences Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1100.00 price target on 2026-09-09. Recent price targets range from $1000.00 to $1250.00.What companies are similar to TLSI?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare TLSI side-by-side with any of them on Quantisnow.How can I track TLSI on Quantisnow?
Quantisnow aggregates TriSalus Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TLSI to receive live email and push alerts on every new disclosure.